Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0028754 (obesity)
 124,988 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Fluoxetine is a highly specific serotonin reuptake inhibitor. In studies that used a dose of 60 mg once daily, fluoxetine-treated patients consistently had greater weight loss than placebo-treated patients. In six double-blind, placebo-controlled studies of 6-8 wk duration, mean weight changes on fluoxetine were approximately 0.5 kg/wk. Longer term studies have shown maximum mean weight loss to occur at 12-20 wk of therapy. Studies have consistently shown improvements in indices of glycemic control as well as weight loss in obese diabetic patients. Safety analysis has been performed on data from 3491 obese patients in controlled clinical trials of up to 52 wk duration. Adverse events with an incidence of greater than 5%, which were reported significantly more frequently by fluoxetine-treated patients, were headache, asthenia, nausea, diarrhea, somnolence, insomnia, nervousness, sweating, and tremor. Fluoxetine is effective, well tolerated, and safe in the treatment of obesity and obese diabetics.
 ...
PMID:Clinical studies with fluoxetine in obesity. 172 31

Adiposis dolorosa or Dercum's disease consists of a painful progressive localized state of obesity with four cardinal symptoms: a) painful circumscribed or diffuse fatty deposits, b) generalized obesity in women usually of menopausal age, c) asthenia, weakness and frequently tendency to fatigue and d) mental phenomena including emotional instability, depression, epilepsy, mental confusion and true dementia. Only a few cases in men have been described. The pain may be treated with intravenous administration of lignocaine or oral mexitil while no causal treatment is known. An illustrative case is reported.
 ...
PMID:[A case of adiposis dolorosa--Dercum's disease]. 150 54

Uvulopalatoplasty was performed (whether or not associated with tonsillectomy and/or septoplasty) in 1,222 cases of chronic rhonchopathy. Among them, 65 cases consisted of pre- and postoperatively registered sleep apnea syndrome. Clinical results were assessed on improvement of preoperative snoring, apneas, morning asthenia, daily sleepiness. Surgery was totally successful in 50% of cases, partially in 35%. Failure was encountered in 15% of cases. Failure or partial improvement are related to the preoperative presence of one or several of five particular risk factors: neck shortness, tongue hypertrophia, retrognathia, obesity and nasal pathology. Surgical complications were rare. Severe rhinolalia occurred in five cases: only three of them were sufficiently to accept plastic reconstruction which was successful.
 ...
PMID:[Clinical results of the surgical treatment of 1222 cases of chronic snoring]. 234 21

Seven patients developed acute hepatitis after receiving Plethoryl for obesity for 4 to 16 weeks. Jaundice was generally associated with or preceded by asthenia, nausea and pruritus. Serum aminotransferase activities were markedly increased whereas alkaline phosphatase and gamma-glutamyltransferase activities were moderately elevated. There was no hepatic failure. In all cases, Plethoryl administration was promptly discontinued. In 6 cases, jaundice disappeared within 2 to 4 weeks, and recovery occurred within 2 to 5 months. In one case, however, jaundice disappeared within 12 weeks and recovery took 10 months.
 ...
PMID:[Hepatitis probably caused by Plethoryl. Apropos of 7 cases]. 337 97

Health risks associated with obesity are well known and compliance with standard regimens for weight reduction is frequently unsatisfactory. Fluoxetine is a specific inhibitor of serotonin re-uptake with very minimal affinity for serotonergic or other receptors. It causes a decrement in food intake in animals. Placebo or fluoxetine was given for up to 8 weeks to non-depressed, otherwise healthy, obese patients given minimal dietary advice. Patients given fluoxetine lost 4.5 +/- 4.0 kg, significantly more than those receiving placebo, 1.4 +/- 0.1 kg. The weight loss was correlated with the degree of obesity in the fluoxetine-treated patients. Asthenia was the only event reported significantly more frequently by fluoxetine-treated patients (23 percent) than by those treated with placebo (3 percent) (P less than 0.01). Fluoxetine appears to be safe and effective in inducing weight loss over periods of up to 8 weeks.
 ...
PMID:Use of a serotonin re-uptake inhibitor, fluoxetine, in the treatment of obesity. 350 94

Adiposis dolorosa (Dercum's disease) is a syndrome of painful adipose tissue which occurs most often in post-menopausal women and is associated with obesity, asthenia, and emotional disturbances. The etiology is uncertain, but is probably multifactorial. Numerous treatments to relieve the pain have generally been unsuccessful. A patient with adiposis dolorosa was treated with intravenous infusions of lidocaine over a two-year period. Relief from pain lasted from two to 12 months after each infusion. A single-blind placebo infusion did not relieve the pain. Lidocaine infusions did not relieve the pain of diabetic neuropathy or of angina in this patient. The mechanism of relief of pain of adiposis dolorosa by lidocaine is uncertain, but previously reported central effects of lidocaine suggest that alterations in the central nervous system may be responsible.
 ...
PMID:Intravenous lidocaine for the treatment of intractable pain of adiposis dolorosa. 712 48

Changes in the quality of life were demonstrated in 38 young women who had undergone intestinal bypass surgery for obesity. After the operation about half the women complained of decreased libido or sexual activity, apparently due to psychological problems related to the development of asthenia secondary to metabolic disturbances. Bypass surgery resulted in a more regular pattern of menstruation but oral contraception was ineffective because of impaired intestinal absorption, perhaps due to a rapid transit time. No absolute contraindication to pregnancy was found but there are many risk-factors for both mother and fetus because of electrolyte disturbances, malnutrition and vitamin deficiency. Infants born to women after bypass surgery were found to have lower birth weights, were shorter, and the placental weight was low. It is necessary for these patients to have close medical supervision. The results of our study show that intestinal bypass surgery in young women has side effects which should not be ignored.
 ...
PMID:Jejuno-ileal bypass surgery in obesity. Gynecological and obstetrical aspects. 724 78

The study of 14 anthropometric findings and indices in a group of primary breast cancer patients with an operable stage of the disease and in the appropriate controls enabled revealing certain differences in the distribution of patients and healthy females with relation to levels of separate anthropometric tests. Some anthropometric findings and their definite numerical values were singled out with respect to which these differences were statistically reliable. The degree of a relatively higher risk of the disease was ascertained in corresponding values of separate indices. Of greatest importance for the increased relative risk of breast cancer were such anthropometric features as obesity (in the extreme age subgroups), asthenia and gynecomastia. With regard to these features the most valuable tests were as follows: Broca's formula, Brugsch index, chest circumference and the ratio of chest circumference to thigh circumference.
 ...
PMID:[Importance of anthropometric parameters in breast cancer]. 746 22

The purpose of this study was to evaluate the effects of the alpha 1-blocking agent terazosin on blood pressure (BP) and blood lipids in a large, variant population of patients with hypertension. A total of 16,917 patients with hypertension were evaluated at 2214 primary and community care facilities; 7808 of these patients had not been treated previously for hypertension; 3928 were switched to terazosin from another antihypertensive agent; and 5181 received terazosin in addition to an agent that had not controlled their hypertension. Terazosin produced highly significant reductions in systolic (-18.2 +/- 0.2 mm Hg) and diastolic (-13.2 +/- 0.1 mm Hg) BP when used as monotherapy (mean dose, 3.1 mg; range, 2 to 10 mg) without causing a significant increase in heart rate. Equal antihypertensive efficacy was demonstrated in men, women, blacks, and whites of all ages, with particular benefit to elderly patients (> or = 65 years of age) with systolic hypertension. Comparative studies indicated that terazosin had equal antihypertensive efficacy in combination with diuretics, beta-blockers, calcium channel blockers, and angiotensin-converting enzyme (ACE) inhibitors. Patients who had not responded to monotherapy with one of these classes of antihypertensive drugs showed significant reductions of BP after terazosin, in the following average doses, was added to diuretics, 3.1 mg; beta-blockers, 3.4 mg; calcium channel blockers, 3.3 mg; and ACE inhibitors, 3.4 mg. Terazosin produced highly significant reductions in blood levels of total cholesterol (-5.0%), triglycerides (-6.1%), and low-density lipoprotein cholesterol (-7.6%) without change in high-density lipoprotein cholesterol when used as monotherapy. Similar favorable effects on blood lipid levels were demonstrated when terazosin was used in combination with all other classes of antihypertensive drugs. The greatest reductions in blood cholesterol (-9.2%) were observed among patients with hyperlipidemia (total cholesterol > or = 240 mg/dL). Terazosin maintained its antihypertensive efficacy and was well tolerated by patients with a variety of concomitant diseases, including congestive heart failure, peripheral vascular disease, chronic obstructive pulmonary disease, benign prostatic hyperplasia, diabetes, and obesity. Adverse effects occurred in 17.9% of patients and caused 2.2% to drop out of the study. The most frequent adverse effects were dizziness (4.8%), headache (2.5%), and asthenia (2.4%). Only 0.4% suffered syncope and 0.2% impotence. These data demonstrate the usefulness of terazosin as monotherapy or add-on therapy for treatment of hypertension.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Alpha 1-blockade for the treatment of hypertension: a megastudy of terazosin in 2214 clinical practice settings. 792 16

Dercum's disease (adiposis dolorosa) is a rare condition characterized by progressively painful fatty deposits, usually, in menopausal women with obesity, asthenia and mental phenomena. We report a case of a 48-year-old woman with recurrent neck swelling and pain in the neck and parotid region, and a review of management of this uncommon problem.
 ...
PMID:Dercum's disease (adiposis dolorosa). 1039 74


1 2 3 Next >>